Literature DB >> 25043619

Angiopoietins promote ovarian cancer progression by establishing a procancer microenvironment.

Melissa K Brunckhorst1, Yin Xu1, Rong Lu1, Qin Yu2.   

Abstract

Despite decades of research, the survival rate of ovarian cancer patients is largely unchanged. Current chemotherapeutic drugs are effective only transiently because patients with advanced disease eventually develop resistance. Thus, there is a pressing need for identifying novel therapeutic targets in ovarian cancer. Mounting evidence suggests that angiopoietins (Angpts) may play an essential role in cancer progression; however, the expression profiles and biological effects of Angpts on ovarian cancer remain largely unknown. Here, we show that, compared with their normal counterparts, expressions of Angpt1, Angpt2, and Angpt4 are increased in ovarian cancer cells and tissues and that human ovarian cancer cells also express the Angpt receptor Tie-2-receptor tyrosine kinase. We show that increased expression of Angpt1, Angpt2, or Angpt4 promotes intraperitoneal growth of ovarian cancers and shortens survival of the experimental mice. We further show, for the first time, that Angpts promote accumulation of cancer-associated fibroblasts and tumor angiogenesis in the ovarian cancer microenvironment, as well as enhance ovarian cancer cell proliferation and invasion in vivo. In addition, we establish a novel function of Angpts in promoting proliferation and invasion and inducing Tie-2 and extracellular signal-regulated kinase 1/2 activation in ovarian cancer-associated fibroblasts. Taken together, these data suggest that the Angpt-Tie-2 functional axis is an important player in ovarian cancer progression and an attractive target for ovarian cancer therapy.
Copyright © 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25043619      PMCID: PMC4116697          DOI: 10.1016/j.ajpath.2014.05.006

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  51 in total

Review 1.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

2.  Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas.

Authors:  M Takahama; M Tsutsumi; T Tsujiuchi; K Nezu; K Kushibe; S Taniguchi; Y Kotake; Y Konishi
Journal:  Clin Cancer Res       Date:  1999-09       Impact factor: 12.531

3.  Angiopoietins 3 and 4: diverging gene counterparts in mice and humans.

Authors:  D M Valenzuela; J A Griffiths; J Rojas; T H Aldrich; P F Jones; H Zhou; J McClain; N G Copeland; D J Gilbert; N A Jenkins; T Huang; N Papadopoulos; P C Maisonpierre; S Davis; G D Yancopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

4.  The prognostic significance of angiogenesis in epithelial ovarian carcinoma.

Authors:  A A Alvarez; H R Krigman; R S Whitaker; R K Dodge; G C Rodriguez
Journal:  Clin Cancer Res       Date:  1999-03       Impact factor: 12.531

5.  Prognostic value of desmoplastic reaction and lymphocytic infiltration in the management of breast cancer.

Authors:  A Cardone; A Tolino; R Zarcone; G Borruto Caracciolo; E Tartaglia
Journal:  Panminerva Med       Date:  1997-09       Impact factor: 5.197

6.  Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system.

Authors:  T N Sato; Y Qin; C A Kozak; K L Audus
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

7.  The Tie receptor tyrosine kinase is expressed by human hematopoietic progenitor cells and by a subset of megakaryocytic cells.

Authors:  P Batard; P Sansilvestri; C Scheinecker; W Knapp; N Debili; W Vainchenker; H J Bühring; M N Monier; E Kukk; J Partanen; M T Matikainen; R Alitalo; J Hatzfeld; K Alitalo
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

8.  Tumor induction of VEGF promoter activity in stromal cells.

Authors:  D Fukumura; R Xavier; T Sugiura; Y Chen; E C Park; N Lu; M Selig; G Nielsen; T Taksir; R K Jain; B Seed
Journal:  Cell       Date:  1998-09-18       Impact factor: 41.582

Review 9.  Ovarian cancer metastasis: integrating insights from disparate model organisms.

Authors:  Honami Naora; Denise J Montell
Journal:  Nat Rev Cancer       Date:  2005-05       Impact factor: 60.716

10.  Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage.

Authors:  H Schnürch; W Risau
Journal:  Development       Date:  1993-11       Impact factor: 6.868

View more
  18 in total

1.  Amplification of chromosome 8q21-qter associated with the acquired paclitaxel resistance of nasopharyngeal carcinoma cells.

Authors:  Wei Li; Yating You; Xiaowei Zhang; Yexun Song; Hong Xiang; Xiaowei Peng; Jiangbo Qin; Guolin Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Oncolytic Virus Affects the RAS Pathway in Cancer: RNA Sequence Analysis.

Authors:  Avishai Samouha; Elisha J Fogel; Sanjay Goel; Radhashree Maitra
Journal:  J Oncol Res Ther       Date:  2021-10-27

3.  High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.

Authors:  Minna Sopo; Hanna Sallinen; Kirsi Hämäläinen; Annukka Kivelä; Seppo Ylä-Herttuala; Veli-Matti Kosma; Leea Keski-Nisula; Maarit Anttila
Journal:  PLoS One       Date:  2020-11-05       Impact factor: 3.240

4.  Role of the angiopoietin/Tie system in pregnancy (Review).

Authors:  D Kappou; S Sifakis; A Konstantinidou; N Papantoniou; D A Spandidos
Journal:  Exp Ther Med       Date:  2015-02-09       Impact factor: 2.447

Review 5.  Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures.

Authors:  Yu Sun
Journal:  Med Res Rev       Date:  2015-01-15       Impact factor: 12.944

6.  Angiopoietin-2 promotes ER+ breast cancer cell survival in bone marrow niche.

Authors:  Hyun Ho Han; Baek Gil Kim; Joo Hyun Lee; Suki Kang; Ji Eun Kim; Nam Hoon Cho
Journal:  Endocr Relat Cancer       Date:  2016-06-27       Impact factor: 5.678

Review 7.  Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.

Authors:  Vera Loizzi; Vittoria Del Vecchio; Giulio Gargano; Maria De Liso; Anila Kardashi; Emanuele Naglieri; Leonardo Resta; Ettore Cicinelli; Gennaro Cormio
Journal:  Int J Mol Sci       Date:  2017-09-14       Impact factor: 5.923

8.  Paracrine effect of GTP cyclohydrolase and angiopoietin-1 interaction in stromal fibroblasts on tumor Tie2 activation and breast cancer growth.

Authors:  Liye Chen; Xin Zeng; Esther Kleibeuker; Francesca Buffa; Alessandro Barberis; Russell D Leek; Ioannis Roxanis; Wei Zhang; Andrew Worth; John S Beech; Adrian L Harris; Shijie Cai
Journal:  Oncotarget       Date:  2016-02-23

Review 9.  Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.

Authors:  Robert Cornelison; Danielle C Llaneza; Charles N Landen
Journal:  Int J Mol Sci       Date:  2017-10-18       Impact factor: 5.923

10.  FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases.

Authors:  Yin Xu; Kaiqiang Wang; Qin Yu
Journal:  Oncotarget       Date:  2016-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.